

# Synthesis of 2,6-*trans*-Tetrahydropyrans Using a Palladium-Catalyzed Oxidative Heck Redox-Relay Strategy

Holly E. Bonfield, Colin M. Edge, Marc Reid, Alan R. Kennedy, David D. Pascoe,\* David M. Lindsay,\* and Damien Valette\*



Cite This: *Org. Lett.* 2024, 26, 2857–2861



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

**ABSTRACT:** The C-aryl-tetrahydropyran motif is prevalent in nature in a number of natural products with biological activity; however, this challenging architecture still requires novel synthetic approaches. We demonstrate the application of a stereoselective Heck redox-relay strategy for the synthesis of functionalized 2,6-*trans*-tetrahydropyrans in excellent selectivity in a single step from an enantiopure dihydropyranyl alcohol, proceeding through a novel *exo*-cyclic migration. The strategy has also been applied to the total synthesis of a *trans*-epimer of the natural product centrolobine in excellent yield and stereoselectivity.



Over the past decade, it has been shown that stereogenic centers can be installed in positions remote from other functionalities in acyclic alkenol systems with high stereoselectivity, via palladium-catalyzed Heck-type redox-relay processes.<sup>1</sup> Following the stereoselective formation of the new C–C bond, the palladium catalyst migrates along the alkyl chain toward the alcohol via successive *syn*- $\beta$ -hydride elimination/*syn*-migratory insertion steps, termed a “chain walk”, terminating with an oxidative deprotonation step that ultimately delivers the corresponding aldehyde or ketone (Figure 1a).<sup>2</sup> Since the seminal publication of this strategy by Sigman and co-workers in 2012,<sup>3</sup> the scope has been expanded significantly for acyclic systems.<sup>1</sup> In particular, the alkenylation of acyclic *O*-aryl enol ethers via a Heck redox-relay strategy has been demonstrated by both Sigman and Correia, using alkenyl triflates and aryl diazonium salts, respectively (Figure 1b).<sup>4–6</sup> Oxidative Heck redox-relay processes are also possible, employing boronic acids instead of halides or pseudohalides. Application of this approach to lactams (Figure 1c)<sup>7</sup> results in arylation  $\alpha$  to the nitrogen atom, followed by partial migration around the ring, furnishing the  $\alpha,\beta$ -unsaturated lactam product.

Since 2009, the University of Strathclyde and GSK have engaged in a collaborative M.Phil./Ph.D. program. This new model of industry/academia partnership supports GSK employees and new graduates to embark on research in a broad range of scientific areas, from chemical biology to process development.<sup>8</sup> As part of this collaborative endeavor, we were inspired to investigate whether the Heck redox-relay strategy could be applied to 6-(hydroxymethyl)-2,3-dihydropyranyl (DHP) alcohols (Figure 1d).

Requiring an ambitious and unprecedented *exo*-cyclic migration process,<sup>9</sup> this approach would represent a new and complementary strategy for accessing 2,6-disubstituted tetrahydropyrans (THPs),<sup>10–14</sup> which are C(sp<sup>3</sup>)-rich, biologically

relevant,<sup>15</sup> and medically important motifs.<sup>16,17</sup> Herein, we disclose the successful realization of this novel approach.

We initiated our study with enantiomerically pure DHP-alcohol, (*R*)-1 (>99:1 er), which is readily available from racemic DHP-alcohol *rac*-1 via enzymatic resolution on a multigram scale (Scheme 1).<sup>18</sup> Pleasingly, reaction of (*R*)-1 with *p*-fluorophenylboronic acid, under conditions similar to those previously reported for oxidative Heck redox-relay reactions<sup>7</sup> [Pd(MeCN)<sub>2</sub>(OTf)<sub>2</sub>, PyrOx ligand **L0**, Cu(OTf)<sub>2</sub>, open to air],<sup>19</sup> validated our proposed strategy, with formation of the desired, product-derived, alcohol 3a as a single diastereoisomer in 46% yield and 97:3 er.

Having identified preliminary conditions for the stereoselective C–C bond formation, we first chose to investigate any potential substrate/catalyst match/mismatch effects in the presence of a chiral ligand by observing the formation of the desired aldehyde in reactions of (*R*)-1 and (*S*)-1 with PyrOx ligands (*S*)-L1 and (*R*)-L1 using <sup>19</sup>F NMR spectroscopy (Figure 2).<sup>20</sup> High yields of the desired *trans*-THP 2a confirmed that (*R*)-1 and (*S*)-L1 are a matched pair, as are (*S*)-1 and (*R*)-L1. For the mismatched catalyst/ligand pairs, complete consumption of the starting material was observed, while the aldehyde product was generated only in small quantities (~10%). It is suspected that under these conditions, a nonligand controlled addition to the opposite face of the alkene also occurs, resulting in products derived from partial

**Special Issue:** Organic Chemistry Driven by Academic-Industrial Collaborations


**Received:** November 28, 2023

**Revised:** January 3, 2024

**Accepted:** January 5, 2024


**Published:** January 10, 2024





**Figure 1.** Heck redox-relay processes and a proposed strategy for accessing 2,6-disubstituted tetrahydropyrans.

### Scheme 1. Heck Redox-Relay Reaction on a Dihydropyranyl Alcohol



**Figure 2.** Match/mismatch data with enantiopure DHP-alcohol and PyrOx L1. Conditions: 2 equiv of  $p\text{-FC}_6\text{H}_4\text{B(OH)}_2$ , 10 mol %  $\text{Pd(MeCN)}_2(\text{OTf})_2$ , 15 mol % PyrOx (S)- or (R)-L1, 4 mol %  $\text{Cu(OTf)}_2$ , DMF (0.1 M), 3 Å MS, air, room temperature.

migration. On this basis, a classical kinetic resolution, where one enantiomer of starting material is converted into the product and the other is left in enriched form, proved to be challenging. While the product was observed in high enantioselectivity, using *rac*-1, enantioenriched starting material was not recovered.<sup>19</sup>

We next undertook an optimization study to probe all components of the reaction process (Table 1). No improvement in yield was observed when a control reaction was performed under an oxygen atmosphere (entry 2). Two

**Table 1.** Investigation of the Reaction Parameters<sup>a</sup>

entry	deviation from the standard conditions	yield (%) <sup>b</sup>	er <sup>c</sup>
1	none	67	>99:1
2	oxygen atmosphere	50	—
3	1 equiv of boronic acid	26	—
4	3 equiv of boronic acid	64	—
5	no Pd, no $\text{Cu(OTf)}_2$	0	—
6	no Pd, 10 mol % $\text{Cu(OTf)}_2$	0	—
7	no $\text{Cu(OTf)}_2$	63	—
8	nitrogen atmosphere	9	—
9	no MS	11	—
10	1 equiv of water	76	99:1
11 <sup>e</sup>	6:10:3 Pd:PyrOx:Cu mole ratio	80 (56 <sup>d</sup> )	99:1
12 <sup>e</sup>	4:6:2 Pd:PyrOx:Cu mole ratio	77 (59 <sup>d</sup> )	>99:1
13 <sup>e</sup>	10:15:4 $\text{Pd(OAc)}_2$ :PyrOx:Cu mole ratio	84 (70 <sup>d</sup> )	99:1

<sup>a</sup>Conditions: 2 equiv of boronic acid, 10 mol %  $\text{Pd(MeCN)}_2(\text{OTf})_2$ , 15 mol % PyrOx L1, 4 mol %  $\text{Cu(OTf)}_2$ , no water, 3 Å molecular sieves, air, unless otherwise stated. <sup>b</sup>The 24 h solution yield of 2a determined by  $^{19}\text{F}\{^1\text{H}\}$  NMR. <sup>c</sup>Enantiomeric ratio determined following reduction of aldehyde 2a to the corresponding alcohol, 3a. <sup>d</sup>Isolated yield following reduction of aldehyde 2a to the corresponding alcohol, 3a. <sup>e</sup>With 1 equiv of water.


equivalents of boronic acid proved to be optimal, with 1 equiv leading to a decreased yield due to competing side reactions (homocoupling, protodeborylation, and phenol formation, entry 1 vs entry 3) and 3 equiv delivering no further increase in yield (entry 4). Control reactions in the absence of palladium and copper or in the absence of palladium only (entry 5 or 6, respectively) confirmed that the palladium(II) species is the active metal catalyst. In the absence of copper(II) triflate, only the rate of the reaction was reduced, but a comparable yield was attained after 24 h compared to standard conditions (entry 7). The exclusion of oxygen or removal of molecular sieves from the reaction led to significantly diminished solution yields, reaching only 9–11% after 24 h (entries 8 and 9).<sup>21</sup> Conversely, the addition of 1 equiv of water had a positive influence on the reaction (entry 10), increasing the yield to 76%.

With this water additive, the palladium:PyrOx (S)-L1:copper loading could be successfully reduced to 4:6:2 (mole percent) while maintaining the excellent yield (entries 11 and 12). Progressing with the lowest catalyst loading (entry 12), 2,6-*trans*-THP derivative 2a was subsequently reduced with sodium borohydride, for ease of isolation, to give the corresponding alcohol, 3a, in 59% yield, >99:1 er, and >20:1 dr. Further screening studies determined that palladium(II) acetate was another viable precatalyst for this transformation, furnishing 3a in 70% yield and 99:1 er.<sup>19</sup>

While two systems that could deliver the desired product in excellent stereoselectivity and comparable yields had been identified, the substrate scope with respect to boronic acid was investigated using the lower catalyst loading of  $\text{Pd(MeCN)}_2(\text{OTf})_2$  with a practical industrial application in mind. Using this strategy, it proved to be possible to selectively generate both enantiomers of the 2,6-*trans*-THP-alcohol product, 3a and *ent*-3a, in comparable yield stereoselectively,

by using the correct combination of DHP-alcohol **1** and PyrOx **L1** (Scheme 2).

### Scheme 2. Arylboronic Acid Substrate Scope



<sup>a</sup>Average of two runs. <sup>b</sup>Conditions: 2 equiv of  $p\text{-FC}_6\text{H}_4\text{B(OH)}_2$ , 10 mol %  $\text{Pd(OAc)}_2$ , 15 mol % PyrOx **L1**, 4 mol %  $\text{Cu(OTf)}_2$ , 1 equiv of water, DMF (0.1 M), 3 Å MS, air, room temperature, 24 h; then  $\text{NaBH}_4$ , MeOH, 0 °C, 3 h. <sup>c</sup>Starting from (S)-DHP-1 using PyrOx (R)-L1.

An X-ray crystal structure of ferrocenoyl-functionalized **3a** confirmed the absolute stereochemistry.<sup>19</sup> The use of other fluorophenylboronic acid isomers proved to be less successful under the optimized reaction conditions.<sup>19</sup> All substrates maintained excellent stereoselectivities throughout. Methoxy-, hydroxy-, benzyloxy-, naphthyl-, and alkyl-substituted boronic acids proved to be successful (**3c-i**). In addition to fluorine, *p*-chlorophenylboronic acid was well tolerated (**3j**); however, yields with *p*-bromo phenylboronic acid (**3n**) were significantly reduced, likely due to the propensity of the bromine to undergo reactions with palladium.


Use of *p*-(trifluoromethyl)phenylboronic acid initially led to the formation of a trace of the aldehyde product. However, when the alternative palladium(II) acetate conditions with higher catalyst loading were employed, an increase in product formation was observed (**3k**). This strategy was also applied to improve the yield of the more electron-deficient systems (**3k**, **3m**, and **3o**); however, *p*-nitrophenyl- and pyrimidylboronic

acids were unreactive under these conditions. Heteroaromatic boronic acids were tolerated (**3o** and **3p**), although the use of 2-furanylboronic acid resulted in a slight erosion of enantioselectivity (**3o**).

Finally, we sought to demonstrate our developed methodology in the synthesis of centrolobine, a natural product that has been found to exhibit antibacterial and antifungal properties.<sup>22</sup> Both *cis*-enantiomers of centrolobine have been isolated, and a number of total syntheses of these naturally occurring stereoisomers have been reported.<sup>23</sup> Given these efforts, interest has shifted toward the unnatural diastereomers,<sup>24</sup> which could be used to develop structure–activity relationships of these cores. More specifically, given that Colobert's synthesis of the *cis*-isomer of centrolobine utilized a *cis*-isomer of **2c** as a key intermediate,<sup>23a,b</sup> we proposed that a *trans*-isomer of centrolobine could be accessed in short order using our developed methodology to more rapidly access this key 2,6-disubstituted THP motif.

To this end, application of our Heck redox-relay conditions to (S)-DHP-alcohol **1** and 4-(methoxy)phenylboronic acid gave *ent*-**2c** in 60% yield (Scheme 3). Then, following the

### Scheme 3. Total Synthesis of *trans*-Centrolobine



approach of Colobert,<sup>23a,b</sup> Wittig reaction of *ent*-**2c** using phosphonium salt **4** afforded alkene **5** in 72% yield. Exposure of **5** to 3.5 mol %  $\text{Pd/Al}_2\text{O}_3$  in the presence of  $\text{H}_2$  resulted in concomitant reduction of the alkene and benzyl deprotection, to afford the (3S,7S)-*trans*-isomer of centrolobine **6** in 68% yield. Given the literature precedent for the ready epimerization of the C-aryl glycoside bond from *trans* to *cis* in intermediates of type **5**,<sup>24d</sup> this approach could be used to rapidly access all four stereoisomers of centrolobine.

In summary, we have applied an oxidative Heck redox-relay strategy to the synthesis of C-aryl-containing 2,6-*trans*-tetrahydropyrans, from enantiopure dihydropyranyl alcohols. Using (R)- or (S)-DHP-alcohol **1**, a range of 2,6-*trans*-tetrahydropyrans, bearing diverse functionality, were generated under mild conditions in excellent stereoselectivity. This motif also provides a synthetic handle for further functionalization, enabling facile access to a diverse set of substrates from a simple building block. We also demonstrated the utility of this approach via the concise synthesis of a *trans*-isomer of the natural product centrolobine.

This approach represents a valuable addition to the redox-relay oxidative Heck toolkit, and the novel *exo*-cyclic migration underpinning this sequence opens up the potential for similar redox-relay chemistry on broader heterocyclic systems.



## ■ ASSOCIATED CONTENT

### Data Availability Statement

The data underlying this study are available in the published article and its [Supporting Information](#).

### SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.orglett.3c03866>.

Experimental procedures, compound characterization data, DFT calculations and coordinates, and X-ray crystal structure data ([PDF](#))

### Accession Codes

CCDC 2093498 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via [www.ccdc.cam.ac.uk/data\\_request/cif](http://www.ccdc.cam.ac.uk/data_request/cif), or by emailing [data\\_request@ccdc.cam.ac.uk](mailto:data_request@ccdc.cam.ac.uk), or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

## ■ AUTHOR INFORMATION

### Corresponding Authors

David D. Pascoe – Drug Substance Development, GSK, Stevenage, Hertfordshire SG1 2NY, U.K.; Email: [david.d.pascoe@gsk.com](mailto:david.d.pascoe@gsk.com)

David M. Lindsay – Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, U.K.; [orcid.org/0000-0003-4498-5094](https://orcid.org/0000-0003-4498-5094); Email: [david.lindsay@strath.ac.uk](mailto:david.lindsay@strath.ac.uk)

Damien Valette – Drug Substance Development, GSK, Stevenage, Hertfordshire SG1 2NY, U.K.; Present Address: MSD R&D Innovation Centre, 120 Moorgate, London EC2M 6UR, U.K.; [orcid.org/0000-0002-1620-3502](https://orcid.org/0000-0002-1620-3502); Email: [damien.x.valette@gmail.com](mailto:damien.x.valette@gmail.com)

### Authors

Holly E. Bonfield – Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, U.K.; Drug Substance Development, GSK, Stevenage, Hertfordshire SG1 2NY, U.K.; Present Address: Apex Molecular Ltd., Alderley Park, Alderley Edge SK10 4TG, U.K.

Colin M. Edge – Drug Substance Development, GSK, Stevenage, Hertfordshire SG1 2NY, U.K.

Marc Reid – Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, U.K.; [orcid.org/0000-0003-4394-3132](https://orcid.org/0000-0003-4394-3132)

Alan R. Kennedy – Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, U.K.; [orcid.org/0000-0003-3652-6015](https://orcid.org/0000-0003-3652-6015)

Complete contact information is available at:

<https://pubs.acs.org/doi/10.1021/acs.orglett.3c03866>

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

The authors thank the GSK/University of Strathclyde Collaborative PhD Programme and the EPSRC for funding via Prosperity Partnership EP/S035990/1. The authors also thank Rita Tailor (GSK) and Steve Jackson (GSK) for preparative and analytical chiral chromatography support and

Marina Economidou (University of Strathclyde and GSK) for assistance in the preparation of the manuscript.

## ■ REFERENCES

- (1) (a) McCartney, D.; Guiry, P. J. The asymmetric Heck and related reactions. *Chem. Soc. Rev.* **2011**, *40*, 5122–5150. (b) Bonfield, H. E.; Valette, D.; Lindsay, D. M.; Reid, M. Stereoselective Remote Functionalization via Palladium-Catalyzed Redox-Relay Heck Methodologies. *Chem. - Eur. J.* **2021**, *27*, 158–174.
- (2) Hilton, M. J.; Xu, L.-P.; Norrby, P.-O.; Wu, Y.-D.; Wiest, O.; Sigman, M. S. Investigating the Nature of Palladium Chain-Walking in the Enantioselective Redox-Relay Heck Reaction of Alkenyl Alcohols. *J. Org. Chem.* **2014**, *79*, 11841–11850.
- (3) Werner, E. W.; Mei, T.-S.; Burckle, A. J.; Sigman, M. S. Enantioselective Heck Arylations of Acyclic Alkenyl Alcohols Using a Redox-Relay Strategy. *Science* **2012**, *338*, 1455–1458.
- (4) Patel, H. H.; Prater, M. B.; Squire, S. O., Jr.; Sigman, M. S. Formation of Chiral Allylic Ethers via an Enantioselective Palladium-Catalyzed Alkenylation of Acyclic Enol Ethers. *J. Am. Chem. Soc.* **2018**, *140*, 5895–5898.
- (5) Polo, E. C.; Wang, M. F.; Angnes, R. A.; Braga, A. A. C.; Correia, C. R. D. Enantioselective Heck Arylation of Acyclic Alkenol Aryl Ethers: Synthetic Applications and DFT Investigation of the Stereoselectivity. *Adv. Synth. Catal.* **2020**, *362*, 884–892.
- (6) For a report of the coupling of aryldiazonium salts and vinyl triflates with acyclic O-alkyl enol ethers, see: Prater, M. B.; Sigman, M. S. Enantioselective Synthesis of Alkyl Allyl Ethers via Palladium-Catalyzed Redox-Relay Heck Alkenylation of O-Alkyl Enol Ethers. *Isr. J. Chem.* **2020**, *60*, 452–460.
- (7) Yuan, Q.; Sigman, M. S. Palladium-Catalyzed Enantioselective Relay Heck Arylation of Enolactams: Accessing  $\alpha,\beta$ -Unsaturated  $\delta$ -Lactams. *J. Am. Chem. Soc.* **2018**, *140*, 6527–6530.
- (8) <https://www.strath.ac.uk/science/chemistry/strathclydegsk/> (accessed 2023-11-02).
- (9) For a Heck redox-relay process on cyclopent-3-ene-1-ols, see: Angnes, R. A.; Oliveira, J. M.; Oliveira, C. C.; Martins, N. C.; Correia, C. R. D. Stereoselective Synthesis of Aryl Cyclopentene Scaffolds by Heck–Matsuda Desymmetrization of 3-Cyclopentenol. *Chem. - Eur. J.* **2014**, *20*, 13117–13121.
- (10) See: Clarke, P. A. Strategies for the Synthesis of Tetrahydropyran-containing Natural Products. *Tetrahedron* **2011**, *67*, 4959 and subsequent papers in this Symposium in Print.
- (11) Taylor, R. D.; MacCoss, M.; Lawson, A. D. G. Rings in Drugs. *J. Med. Chem.* **2014**, *57*, 5845–5859.
- (12) Gomtsyan, A. Heterocycles in Drugs and Drug Discovery. *Chem. Heterocycl. Compd.* **2012**, *48*, 7–10.
- (13) (a) Larrosa, I.; Romea, P.; Urpí, F. Synthesis of six-membered oxygenated heterocycles through carbon–oxygen bond-forming reactions. *Tetrahedron* **2008**, *64*, 2683–2723. (b) Nasir, N. M.; Ermanis, K.; Clarke, P. A. Strategies for the construction of tetrahydropyran rings in the synthesis of natural products. *Org. Biomol. Chem.* **2014**, *12*, 3323–3335.
- (14) Tong, R.; Zhang, Z. Synthetic Approaches to 2,6-trans-Tetrahydropyrans. *Synthesis* **2017**, *49*, 4899–4916.
- (15) (a) Kitamura, K.; Ando, Y.; Matsumoto, T.; Suzuki, K. Total Synthesis of Aryl C-Glycoside Natural Products: Strategies and Tactics. *Chem. Rev.* **2018**, *118*, 1495–1598. (b) Ghoulilem, J.; Tran, C.; Grimblat, N.; Retailleau, P.; Alami, M.; Gandon, V.; Messaoudi, S. Diastereoselective Pd-Catalyzed Anomeric C(sp<sup>3</sup>)–H Activation: Synthesis of  $\alpha$ -(Hetero)aryl C-Glycosides. *ACS Catal.* **2021**, *11*, 1818–1826.
- (16) Lovering, F.; Bikker, J.; Humblet, C. Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success. *J. Med. Chem.* **2009**, *52*, 6752–6756.
- (17) (a) Surivet, J.-P.; Zumbrunn, C.; Bruyère, T.; Bur, D.; Kohl, C.; Locher, H. H.; Seiler, P.; Ertel, E. A.; Hess, P.; Enderlin-Paput, M.; Enderlin-Paput, S.; Gauvin, J.-C.; Mirre, A.; Hubschwerlen, C.; Ritz, D.; Rueedi, G. Synthesis and Characterization of Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Antibacterial Activity

against Gram-Negative Bacteria. *J. Med. Chem.* **2017**, *60*, 3776–3794. (b) Ortalli, M.; Varani, S.; Cimato, G.; Veronesi, R.; Quintavalla, A.; Lombardo, M.; Monari, M.; Trombini, C. Evaluation of the Pharmacophoric Role of the O–O Bond in Synthetic Antileishmanial Compounds: Comparison between 1,2-Dioxanes and Tetrahydropyrans. *J. Med. Chem.* **2020**, *63*, 13140–13158. (c) Singh, P.; Bhardwaj, A. Mono-, Di-, and Triaryl Substituted Tetrahydropyrans as Cyclooxygenase-2 and Tumor Growth Inhibitors. Synthesis and Biological Evaluation. *J. Med. Chem.* **2010**, *53*, 3707–3717.

(18) (a) Karageorgis, G.; Dow, M.; Aimon, A.; Warriner, S.; Nelson, A. Activity-Directed Synthesis with Intermolecular Reactions: Development of a Fragment into a Range of Androgen Receptor Agonists. *Angew. Chem., Int. Ed.* **2015**, *54*, 13538–13544. (b) Jagtap, P. G.; Chen, Z.; Koppetsch, K.; Piro, E.; Fronce, P.; Southan, G. J.; Klotz, K.-N. Synthesis of (*R*)-3,4-dihydro-2*H*-pyran-2-carboxaldehyde: application to the synthesis of potent adenosine A<sub>2A</sub> and A<sub>3</sub> receptor agonist. *Tetrahedron Lett.* **2009**, *50*, 2693.

(19) See the [Supporting Information](#) for further details.

(20) Masamune, S.; Choy, W.; Petersen, J. S.; Sita, L. R. Double Asymmetric Synthesis and a New Strategy for Stereochemical Control in Organic Synthesis. *Angew. Chem., Int. Ed.* **1985**, *24*, 1–30.

(21) Mei, T.-S.; Werner, E. W.; Burckle, A. J.; Sigman, M. S. Enantioselective Redox-Relay Oxidative Heck Arylations of Acyclic Alkenyl Alcohols using Boronic Acids. *J. Am. Chem. Soc.* **2013**, *135*, 6830–6833.

(22) Jurd, L.; Wong, R. Y. Diarylheptanoid and other phenolic constituents of *Centrolobium* species. *Aust. J. Chem.* **1984**, *37*, 1127–1133. (b) de Albuquerque, I. L.; Galeffi, C.; Casinovi, C. G.; Marini-Bettolo, G. B. A Tetrahydropyran Derivative Isolated from *Centrolobium* Wood. *Gazz. Chim. Ital.* **1964**, *94*, 287–295. (c) Alegrio, L. V.; Braz-Filho, R.; Gottlieb, O. R. Diarylheptanoids and isoflavonoids from *Centrolobium* species. *Phytochemistry* **1989**, *28*, 2359–2362.

(23) (a) Colobert, F.; Des Mazery, R.; Solladié, G.; Carreño, M. C. First Enantioselective Total Synthesis of (–)-Centrolobine. *Org. Lett.* **2002**, *4*, 1723–1725. (b) Carreno, M. C.; Des Mazery, R.; Urbano, A.; Colobert, F.; Solladié, G. Reductive Cyclizations of Hydroxysulfinyl Ketones: Enantioselective Access to Tetrahydropyran and Tetrahydrofuran Derivatives. *J. Org. Chem.* **2003**, *68*, 7779–7787. (c) Chan, K.-P.; Loh, T.-P. Prins Cyclizations in Silyl Additives with Suppression of Epimerization: Versatile Tool in the Synthesis of the Tetrahydropyran Backbone of Natural Products. *Org. Lett.* **2005**, *7*, 4491–4494. (d) Böhrsch, V.; Blechert, S. A concise synthesis of (–)-centrolobine via a diastereoselective ring rearrangement meta-thesis–isomerisation sequence. *Chem. Commun.* **2006**, 1968–1970. (e) Takeuchi, T.; Matsushashi, M.; Nakata, T. Total synthesis of (–)-centrolobine. *Tetrahedron Lett.* **2008**, *49*, 6462–6465.

(24) (a) Reddy, C. R.; Madhavi, P. P.; Chandrasekhar, S. Asymmetric Synthesis of (–)-6-epi-Centrolobine. *Synthesis* **2008**, 2939–2942. (b) Schmidt, B.; Hölter, F. A Stereodivergent Synthesis of All Stereoisomers of Centrolobine: Control of Selectivity by a Protecting-Group Manipulation. *Chem. - Eur. J.* **2009**, *15*, 11948–11953. (c) Sudarshan, K.; Aidhen, I. S. Synthesis of (+)-Centrolobine and Its Analogues by Using Acyl Anion Chemistry. *Eur. J. Org. Chem.* **2013**, *2013*, 2298–2302. (d) Nagarjuna, B.; Thirupathi, B.; Venkata Rao, C.; Mohapatra, D. K. Chemoenzymatic total synthesis of four stereoisomers of centrolobine. *Tetrahedron Lett.* **2015**, *56*, 4916–4918.